Cinical Trials: Pilot Study of Redirected Autologous Tcells Engineered to Contain Anti-CD19 Attached to TCR and 4-1BB Signaling Domains in Patient With Chemotherapy Resistant or Refractory CD19+ Leukemia and Lymphoma

Sponsor and Collaborators

Abramson Cancer Center of the University of Pennsylvania

Contact

David L. Porter

215-662-2867

admin@ctsrmc.org

Principal Investigator

David Porter, Abramson Cancer Center of the University of Pennsylvania

ClinicalTrials.gov Identifier

NCT01029366